---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-23-001174"
form_type: "8-K"
ticker: "ARCT"
cik: "0001768224"
company_name: "Arcturus Therapeutics Holdings Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T12:04:03.428121+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Arcturus' JV ARCALIS awarded $115M in Japanese government grants; achieves $17.5M CSL flu milestone

## Summary
- ARCALIS, Arcturus' 49%-owned joint venture, receives $115M in two grants to build a cGMP mRNA factory in Minamisoma, Japan.
- LUNAR-FLU program achieves $17.5M development milestone from CSL Seqirus; funds used for flu program development activities.
- The factory will support cGMP production of mRNA drug substance and drug product for Arcturus' STARR mRNA vaccines.
- CSL Seqirus is exclusive global licensee for mRNA vaccines against COVID-19, flu, and three other respiratory diseases.

## SEC filing metadata
- accession: 0001193805-23-001174
- form_type: 8-K
- ticker: ARCT
- cik: 0001768224
- company_name: Arcturus Therapeutics Holdings Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1768224/000119380523001174/0001193805-23-001174-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1768224/000119380523001174/e618874_8k-arct.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-23-001174
- JSON: https://secwatch.observer/filing/0001193805-23-001174.json
- Plain text: https://secwatch.observer/filing/0001193805-23-001174.txt

## Key facts
- Material Agreements
  Arcturus Therapeutics Holdings Inc. entered into CSL Collaboration Agreement with Seqirus, Inc., a part of CSL Seqirus (effective 2022-12-08).
  - Action: entry
  - Agreement: collaboration
  - Counterparty: Seqirus, Inc., a part of CSL Seqirus
  - Effective: 2022-12-08
  source text: the Company entered into the CSL Collaboration Agreement with CSL Seqirus for the global exclusive rights to research, develop, manufacture and commercialize Arcturus’ self-amplifying mRNA vaccines against COVID-19, influenza and three other respiratory infectious diseases with nonexclusive rights to pandemic pathogens
  evidence_url: https://www.sec.gov/Archives/edgar/data/1768224/000119380523001174/0001193805-23-001174-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.